Hyperthyroid in Keytruda - how severe and when it was recovered? (a real world drug study)

Summary:

We study how severe was Hyperthyroid, when it was recovered, drug effectiveness, race, and more among people who take Keytruda (pembrolizumab). This phase IV clinical study is created by eHealthMe based on reports submitted to eHealthMe, and is updated regularly.

What is Keytruda?

Keytruda has active ingredients of pembrolizumab. It is often used in renal cell carcinoma. eHealthMe is studying from 57,404 Keytruda users. Check the latest studies of Keytruda.

What is Hyperthyroid?

Hyperthyroid is found to be associated with 1,084 drugs and 1,420 conditions by eHealthMe. Check the latest studies of Hyperthyroid.

On Jun, 20, 2026

1 person who has Hyperthyroid while taking Keytruda was studied.

Severity of Hyperthyroid *:

least: 0.0 %
moderate: 100 %
severe: 0.0 %
most severe: 0.0 %

When people recovered from Hyperthyroid:

n/a

Effectiveness of Keytruda *:

not at all: 0.0 %
somewhat: 0.0 %
moderate: 0.0 %
high: 100 %
very high: 0.0 %

Race of the people *:

African American, Non-Hispanic: 0.0 %
American Indian/Alaska Native: 0.0 %
Asian: 0.0 %
Hispanic: 0.0 %
Native Hawaiians/Pacific Islanders: 0.0 %
Two or more races: 0.0 %
White, Non-Hispanic: 100 %

Time on Keytruda *:

Gender of people when taking Keytruda *:

female: 0.0 %
male: 100 %

Age of people when taking Keytruda *:

Conditions people have *:

Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 100.00%

* Approximation only. Some reports may have incomplete information.

Do you take Keytruda and have Hyperthyroid?

Check whether Hyperthyroid is associated with a drug or a condition

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Related studies

Hyperthyroid in Keytruda

How the study uses the data?

The study is based on pembrolizumab (the active ingredients of Keytruda). Other drugs that have the same active ingredients (e.g. generic drugs) are considered. Dosage of drugs is not considered in the study.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.